Older patients left behind in progress against lung cancer, Yale study shows

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition

Montefiore Einstein Comprehensive Cancer Center announced that its lung cancer team has been recognized by the International Association for the Study of Lung Cancer for delivering outstanding care. The announcement was made during the IASLC annual meeting in Barcelona.

October 03, 2025

Vol.51 No.36

Clinical Roundup

American Lung Association launches campaign to address barriers to lung cancer screening and care

The American Lung Association launched a campaign to raise awareness about lung cancer screening and biomarker testing, shaped by the voices of people diagnosed with lung cancer and their caregivers across the country.

October 03, 2025

Vol.51 No.36

Drugs & Targets

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

FDA has granted a approval for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as a maintenance treatment for adults with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

October 03, 2025

Vol.51 No.36

Clinical Roundup

Mammograms may benefit women well into their 80s, UCLA study finds

For many older women, the question of whether to continue breast cancer screening has been uncertain. While most guidelines recommend mammograms up to age 74, advice for women 75 and older has been less clear.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.

September 26, 2025

Vol.51 No.35

In Brief

Yale receives renewed lung cancer SPORE grant from NCI

Yale Cancer Center’s Specialized Program of Research Excellence in Lung Cancer was awarded a renewal grant from NCI for year 11 of the program.

September 19, 2025

Vol.51 No.34

Older patients left behind in progress against lung cancer, Yale study shows

YOU MAY BE INTERESTED IN

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition

American Lung Association launches campaign to address barriers to lung cancer screening and care

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

Mammograms may benefit women well into their 80s, UCLA study finds

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Yale receives renewed lung cancer SPORE grant from NCI

Renew today!

Subscriber content

Never miss an issue!

Login